🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Docon offloads 10% stake in Thyrocare for Rs 668 Cr

EntrackrEntrackr · 22d ago
Docon offloads 10% stake in Thyrocare for Rs 668 Cr
Medial

Docon Technologies Pvt Ltd, a promoter entity of Thyrocare Technologies, has sold 53.33 lakh equity shares representing around 10% of the company’s total paid-up capital through open market transactions on October 24, 2025. The sale was valued at Rs 667.7 crore at an average price of Rs 1,252 per share, according to a stock exchange filing. Following the transaction, Docon’s shareholding in Thyrocare has come down from 71% to 61% and continues to remain a promoter of the diagnostics chain with 3.2 crore shares. The block sale saw strong participation from domestic mutual funds. Among the key buyers were ICICI Prudential Mutual Fund, which purchased 17.49 lakh shares worth Rs 218.9 crore, and Aditya Birla Sun Life Mutual Fund, which picked up 10.33 lakh shares for Rs 129.3 crore. Other prominent investors included HSBC Mutual Fund Midcap Fund (6.66 lakh shares for Rs 83.4 crore), HDFC Mutual Fund (4.44 lakh shares for Rs 55.5 crore), and Eastspring Investments India Consumer Equity Open Limited (3.19 lakh shares for Rs 40 crore). The stake sale comes on the back of leadership transition within the PharmEasy-Thyrocare group. In August 2025, PharmEasy’s co-founder and CEO Siddharth Shah stepped down from his executive role to become the company’s Vice Chairman, while Thyrocare’s chief Rahul Guha was elevated as the new MD and CEO of API Holdings, the parent entity of PharmEasy and Thyrocare. Guha continues to lead Thyrocare alongside his expanded responsibilities at API. Thyrocare recently announced its financial numbers for the second quarter of the ongoing fiscal year FY26, posting a strong performance in the quarter. The company’s revenue from operations grew 22% year-on-year (YoY) to Rs 216.5 crore in Q2 FY26 from Rs 177.36 crore in Q2 FY25. Thyrocare’s profit jumped 81% YoY to Rs 47.9 crore in Q2 FY26, compared to Rs 26.4 crore in the corresponding quarter last year. For the first half of FY26, the company recorded a net profit that grew 71% to Rs 86.1 crore from Rs 50.4 crore in H1 FY25.

Related News

QRG Investments offloads Awfis’ shares worth Rs 141 Cr

EntrackrEntrackr · 1m ago
QRG Investments offloads Awfis’ shares worth Rs 141 Cr
Medial

QRG Investments offloads Awfis’ shares worth Rs 141 Cr QRG Investment has sold its 82% stake in co-working solutions firm Awfis through a bulk deal. The investor has offloaded its 24,07,800 shares at Rs 585.14 per share for Rs 140.9 crore. According to a corporate disclosure on the National Stock Exchange (NSE), the investor has offloaded its 24,07,800 shares at Rs 585.14 per share for Rs 140.9 crore. Prior to this, QRG had offloaded 3,67,408 Awfis’ shares last month, aggregating to Rs 22 crore, taking its total disinvestment to 94% of its overall stake in the company. As of March 2025, QRG Investments owned 29,39,074 shares of Awfis, forming a total of 4.11% of Awfis' total captable. QRG Investments and Holdings Limited, the promoter holding arm of QRG Group, operates as a mid-tier NBFC. On the other hand, HSBC MUTUAL FUND picked up 9,18,300 shares of Awfis at a price of Rs 585 per share, which totaled to Rs 53.72 crore in a bulk deal. Earlier this month, VBAP Holdings Private Limited also sold its 23.6% stake in Awfis through a bulk deal for Rs 56.8 crore. Awfis’ revenue from operations grew 30% year-on-year to Rs 335 crore in Q1 FY26 from Rs 258 crore in the same quarter last year. The company’s profit surged 3.5X to Rs 10 crore in Q1 FY26, from Rs 2.8 crore in Q1 FY25 in the same period. Awfis’ stock is trading at Rs 577 with a total market capitalization of Rs 4,126 crore.

QRG Investments offloads Awfis’ shares worth Rs 22 Cr

EntrackrEntrackr · 1m ago
QRG Investments offloads Awfis’ shares worth Rs 22 Cr
Medial

Snippets QRG Investments offloads Awfis’ shares worth Rs 22 Cr QRG Investments and Holdings Limited has sold 3,67,408 shares of Awfis at a price of Rs 591.17 per share aggregating to Rs 21.94 crore in a bulk deal. QRG Investments and Holdings Limited, the promoter holding arm of QRG Group and a key shareholder in Havells India, operates as a mid-tier NBFC. It manages a diverse portfolio that includes startup investments, listed stocks, venture debt, structured credit, REITs/InvITs, and private businesses across sectors such as healthcare, EVs, and pharmaceuticals. Awfis on its Annual General Meeting yesterday reappointed Rajesh Kharabanda as Non-Executive Director who retires by rotation. Awfis’ revenue from operations grew 30% year-on-year to Rs 335 crore in Q1 FY26 from Rs 258 crore in the same quarter last year. The company’s profit surged 3.5X to Rs 10 crore in Q1 FY26, from Rs 2.8 crore in Q1 FY25 in the same period. Awfis’ stock is trading at Rs 577 (as of 10:40 AM) with a total market capitalization of Rs 4,131 crore.

Thyrocare posts Rs 216 Cr revenue in Q2 FY26; profit rises 81%

EntrackrEntrackr · 1m ago
Thyrocare posts Rs 216 Cr revenue in Q2 FY26; profit rises 81%
Medial

Thyrocare posts Rs 216 Cr revenue in Q2 FY26; profit rises 81% Diagnostics major Thyrocare Technologies posted a strong performance in the second quarter of FY26, reporting strong growth in both revenue and profit, supported by higher testing volumes across its diagnostic and imaging segments. The company’s consolidated revenue from operations grew 22% year-on-year (YoY) to Rs 216.5 crore in Q2 FY26 from Rs 177.36 crore in Q2 FY25, as per its filings with the stock exchanges. Sequentially, the company’s revenue rose 12% from Rs 193 crore in Q1 FY26. The growth was primarily driven by the diagnostic testing services segment, which contributed over 93% of total revenue, while the imaging services segment (including PET-CT and radiopharmaceuticals) accounted for Rs 14.2 crore during the quarter. Thyrocare’s profit after tax jumped 81% YoY to Rs 47.9 crore in Q2 FY26, compared to Rs 26.4 crore in the corresponding quarter last year, aided by margin expansion and operational leverage. For the first half of FY26, the company recorded a net profit that grew 71% to Rs 86.1 crore from Rs 50.4 crore in H1 FY25. The company’s EBITDA margin improved to 33%, with total expenses growing at a slower pace (10% YoY) than revenue. During the quarter, the cost of materials consumed rose to Rs 59.8 crore, while employee benefits expenses stood at Rs 33.2 crore. Thyrocare’s board has also approved a 2:1 bonus issue, allotting two fully paid-up shares for every existing share held by shareholders as of the record date. The board also declared an interim dividend of Rs 7 per share for FY26, with October 24 set as the record date. At the end of H1FY26, Thyrocare had a total current asset of Rs 323 crore with cash and bank balances of Rs 70 crore. The company is currently traded at Rs 1270.5 (as on 12.35 PM) with the total market capitalization of Rs 6,754 crore ($767 million).

Download the medial app to read full posts, comements and news.